Prelude Therapeutics Incorporated logo

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 September 2020

Next earnings report:

02 August 2024

Last dividends:

N/A

Next dividends:

N/A
$202.14 M
-88%vs. 3y high
55%vs. sector
-vs. 3y high
-vs. sector
-82%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 03 Jul 2024 18:10:22 GMT
$3.68-$0.05(-1.34%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PRLD Latest News

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
globenewswire.com03 June 2024 Sentiment: NEUTRAL

WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.

All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
Zacks Investment Research04 October 2023 Sentiment: POSITIVE

Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
GlobeNewsWire11 April 2023 Sentiment: POSITIVE

Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline

What type of business is Prelude Therapeutics Incorporated?

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

What sector is Prelude Therapeutics Incorporated in?

Prelude Therapeutics Incorporated is in the Healthcare sector

What industry is Prelude Therapeutics Incorporated in?

Prelude Therapeutics Incorporated is in the Biotechnology industry

What country is Prelude Therapeutics Incorporated from?

Prelude Therapeutics Incorporated is headquartered in United States

When did Prelude Therapeutics Incorporated go public?

Prelude Therapeutics Incorporated initial public offering (IPO) was on 25 September 2020

What is Prelude Therapeutics Incorporated website?

https://www.preludetx.com

Is Prelude Therapeutics Incorporated in the S&P 500?

No, Prelude Therapeutics Incorporated is not included in the S&P 500 index

Is Prelude Therapeutics Incorporated in the NASDAQ 100?

No, Prelude Therapeutics Incorporated is not included in the NASDAQ 100 index

Is Prelude Therapeutics Incorporated in the Dow Jones?

No, Prelude Therapeutics Incorporated is not included in the Dow Jones index

When does Prelude Therapeutics Incorporated report earnings?

The next expected earnings date for Prelude Therapeutics Incorporated is 02 August 2024